Resmed Corp.

ResMed Corp. (often referred to as ResMed Inc.) is a publicly traded medical equipment company that develops, manufactures, and distributes cloud-connectable medical devices for the treatment and management of sleep-disordered breathing and other respiratory conditions. Headquartered in San Diego, California, ResMed was founded in Australia in June 1989. The company is listed on the New York Stock Exchange (NYSE: RMD) and the Australian Securities Exchange (ASX: RMD). As of May 2026, ResMed has a market capitalization of approximately $30.16 billion USD and employs around 10,600 people worldwide. Its trailing twelve-month revenue as of March 31, 2026, was $5.538 billion.

ResMed's primary offerings include cloud-connected Continuous Positive Airway Pressure (CPAP) devices, masks, and accessories for sleep apnea treatment, as well as bilevel devices and ventilators for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company also provides digital health solutions and out-of-hospital software platforms that support home healthcare agencies and senior care settings. These digital solutions aim to streamline transitions of care and provide clinical data for patients and healthcare providers.

In terms of patent litigation, ResMed Corp. appears to be an active two-way litigant, engaging in both defending its products and asserting its intellectual property. The company has a balanced patent litigation posture, with one tracked case as a plaintiff and one as a defendant. Both cases involve Fractus, S.A., indicating a direct dispute between the two entities rather than ResMed exclusively fending off non-practicing entities.

Notable cases include Resmed Corp. v. Fractus, S.A., where ResMed is the plaintiff in a Patent Trial and Appeal Board (PTAB) proceeding initiated on January 2, 2026. Conversely, ResMed Inc. is a defendant in Fractus, S.A. v. ResMed Inc. et al., filed on October 9, 2025, in the U.S. District Court for the Southern District of California. This suggests a concurrent and possibly related set of challenges concerning patent validity and infringement between ResMed and Fractus, S.A.